Wall Street Zen Upgrades Edwards Lifesciences (NYSE:EW) to "Buy"

Key Points

• Wall Street Zen upgraded Edwards Lifesciences to “Buy” from “Hold.” MarketBeat reports a consensus “Moderate Buy” rating from 23 analysts, with an average price target of $100.27 versus the stock’s recent price of $84.54.
• Edwards posted quarterly EPS of $0.78, beating the $0.74 consensus estimate, while revenue reached $1.74 billion and rose 13.6% year over year. The company maintained 2026 earnings guidance of $2.95–$3.05 per share.
• Expanded Medicare coverage for TAVR procedures could broaden the eligible patient base and support future demand, although the stock’s elevated valuation—about 49 times earnings—may leave it sensitive to market weakness or slower-than-expected volume growth.

Edwards Lifesciences (NYSE:EW - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Other equities research analysts have also issued research reports about the company. UBS Group initiated coverage on Edwards Lifesciences in a research note on Tuesday, July 28th. They set a "buy" rating and a $110.00 price target on the stock. Evercore reaffirmed an "outperform" rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research report on Monday, July 6th. BTIG Research reiterated a "buy" rating and issued a $110.00 target price on shares of Edwards Lifesciences in a research note on Friday. Mizuho boosted their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 15th. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $100.27.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $84.54 on Friday. The business's fifty day simple moving average is $89.16 and its 200-day simple moving average is $85.79. The company has a market cap of $48.68 billion, a PE ratio of 48.59, a PEG ratio of 2.28 and a beta of 0.85. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 12-month low of $72.30 and a 12-month high of $96.29.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. The firm had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business's revenue for the quarter was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts expect that Edwards Lifesciences will post 3 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP Andrew M. Dahl sold 544 shares of the firm's stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the completion of the transaction, the senior vice president directly owned 14,868 shares in the company, valued at $1,353,880.08. This trade represents a 3.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Daniel Lippis sold 619 shares of Edwards Lifesciences stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the sale, the vice president directly owned 40,034 shares of the company's stock, valued at $3,684,329.02. This trade represents a 1.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 5,664 shares of company stock valued at $511,918. Company insiders own 0.31% of the company's stock.

Institutional Trading of Edwards Lifesciences

Institutional investors and hedge funds have recently bought and sold shares of the business. Rehmann Capital Advisory Group raised its holdings in shares of Edwards Lifesciences by 2.1% during the fourth quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company's stock worth $546,000 after purchasing an additional 130 shares during the last quarter. Quadrant Capital Group LLC boosted its holdings in Edwards Lifesciences by 0.9% in the fourth quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company's stock valued at $1,288,000 after purchasing an additional 136 shares during the last quarter. Stephens Inc. AR boosted its holdings in Edwards Lifesciences by 5.4% in the fourth quarter. Stephens Inc. AR now owns 2,799 shares of the medical research company's stock valued at $239,000 after purchasing an additional 144 shares during the last quarter. Aspen Investment Management Inc grew its position in Edwards Lifesciences by 1.5% during the 4th quarter. Aspen Investment Management Inc now owns 10,381 shares of the medical research company's stock worth $885,000 after purchasing an additional 150 shares during the period. Finally, NorthRock Partners LLC grew its position in Edwards Lifesciences by 1.0% during the 2nd quarter. NorthRock Partners LLC now owns 16,191 shares of the medical research company's stock worth $1,465,000 after purchasing an additional 153 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences News Roundup

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: CMS expands TAVR coverage: The Centers for Medicare and Medicaid Services will extend Medicare coverage to certain patients with severe aortic stenosis who do not yet have symptoms. The broader eligible patient population could increase demand for Edwards’ TAVR valves and procedures, a particularly important growth opportunity for the company. CMS expands TAVR Medicare coverage to asymptomatic patients
• Positive Sentiment: Company welcomes the policy: Edwards said the national coverage determination should improve patient access to TAVR while reinforcing the role of multidisciplinary Heart Teams. The company also reaffirmed its 2026 financial guidance following the decision, suggesting no immediate deterioration in its outlook. Edwards Lifesciences Reaffirms 2026 Guidance Following Medicare TAVR Decision
• Positive Sentiment: Analysts remain bullish: Citi initiated or reiterated a Buy view, while BTIG reaffirmed its Buy rating with a $110 price target. William Blair also maintained a Buy rating, citing the expanded TAVR coverage and inclusion of asymptomatic patients. These targets imply substantial potential upside from recent trading levels. Analyst Buy Rating on Edwards Lifesciences
• Neutral Sentiment: Why the stock may still be under pressure: The reports identify no new company-specific negative catalyst. Investors may be waiting for evidence that the CMS change translates into procedure volumes and revenue, while Edwards’ relatively elevated valuation—about 49 times earnings—could make the shares sensitive to profit-taking or broader market weakness.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation NYSE: EW is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company's portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.